P
Pathalys Pharma
Hemodialysis remains the most widely used treatment for patients with end-stage kidney disease
About Pathalys Pharma
Pathalys Pharma, Inc. is a biopharmaceutical startup dedicated to improving the lives of patients suffering from Chronic Kidney Disease (CKD). The company operates in the healthcare sector, specifically focusing on the development of enhanced therapeutics for CKD management. Their primary clients are patients with end-stage kidney disease, a condition that currently relies heavily on hemodialysis treatment.
Pathalys is particularly focused on addressing the unmet needs in this sector, one of which is the improved treatment for secondary hyperparathyroidism (SHPT). SHPT is a condition often caused by kidney failure and vitamin D deficiency, leading to the overproduction of parathyroid hormone (PTH). Pathalys aims to tackle this issue with the development of upacicalcet, a novel calcimimetic. Calcimimetics are drugs that mimic the action of calcium on tissues, helping to treat SHPT.
The company's business model revolves around the research, development, and distribution of these specialized therapeutics. They generate revenue through the sale of these drugs to healthcare providers and patients. Pathalys was initially funded by Catalys Pacific and DaVita Venture Group, indicating a strong backing and potential for growth in the biopharmaceutical industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Raleigh, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 82.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2024 | $105M | $420M | JP Morgan · KB Investment · Catalys Pacific · Japan Post Investment | ↗ |
| EARLY VCOther financing | Jan 2023 | $75M | $300M | OrbiMed · Catalys Pacific · Abingworth · The Carlyle Group | ↗ |
Growth signals
Latest recorded traffic for Pathalys Pharma is 2.5K monthly website visits, up 150% over the last three months. Pathalys Pharma's team grew 23.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Catalys Pacific
DaVita Venture Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pathalys Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pathalys Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.